• Yulia Vyzhga N. I. Pirogov Vinnytsya National Medical University
Keywords: juvenile idiopathic arthritis, children, inflammatory markers, treatment, NF-kB, cytokines


The activity of the juvenile idiopathic arthritis evaluates the speed of the process progression, intense of its clinical manifestation, effect of the carried treatment.

The aim of our study was to estimate changes of the inflammatory response signs as well as content of NF-kB due to basic therapy of the JIA.

Materials and methods. At our study, we had checked 68 children with JIA, who passed their treatment at Vinnytsya regional children’s hospital within the period from 2011 to 2014 years.

Results. At the patients we studied currency of the JIA was characterized with articular variant of the disease, mainly in monoarthritis type. Laboratory activity of the inflammatory response characterized with increased content of the C-reactive protein (71.2±3.7 %), inflammatory cytokines – ІL-1β (54.8±4.1 %) and ІL-6 (56.2±2.4 %), as well high quantity of the nuclear factor-kB (70.5±3.1 %). Currency of the JIA in children characterized with high increasing of the inflammatory response signs especially C-reactive protein (6.55(4.2;9.8)), ІL-1β (7.3(3.5;11.9)), ІL-6 (6.8(4.5;10.6)) and NF-kB (6.76 (4.8; 9.1)), that are in correlative connections with clinical signs (number of the injured and swelled joints, evaluation of the general condition of the child according to doctors and own response) of the disease activity (rxy = +0.34 up to 0.62, p< 0.01).

Conclusion. During the managing of the basic therapy in children with JIA we estimated decreasing of the IL-1β content in patients at the background of methotrexate administration (38.7±3.7 %), at the second group with use of sulfasalazine (28.5±3.5 %) and the third with leflunomide prescription (29.1±5.1 %), but significant decreasing of the ІL-6 content, that is one of the main inflammatory mediators and as well NF-kB was found just in group of the patients with methotrexate administration (on 36.3±3.8 % and 32.4±2.4 % for NF-kB).


Download data is not yet available.

Author Biography

Yulia Vyzhga, N. I. Pirogov Vinnytsya National Medical University

PhD, Associate professor

Department of pediatric No. 2


Ghosh, S., May, M. J., Kopp, E. B. (1998). NF-κB and Rel proteins: Evolutionarily Conserved Mediators of Immune Responses. Annual Review of Immunology, 16 (1), 225–260. doi: http://doi.org/10.1146/annurev.immunol.16.1.225

Hahn, Y.-S., Kim, J.-G. (2010). Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis. Korean Journal of Pediatrics, 53 (11), 921–930. doi: http://doi.org/10.3345/kjp.2010.53.11.921

Van den Ham, H.-J., de Jager, W., Bijlsma, J. W. J., Prakken, B. J., de Boer, R. J. (2009). Differential cytokine profiles in juvenile idiopathic arthritis subtypes revealed by cluster analysis. Rheumatology, 48 (8), 899–905. doi: http://doi.org/10.1093/rheumatology/kep125

Kemper, A. R., Van Mater, H. A., Coeytaux, R. R., Williams, J. W., Sanders, G. D. (2012). Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. BMC Pediatrics, 12 (1), 1471–1479. doi: http://doi.org/10.1186/1471-2431-12-29

Isennock, M., Grosel, J. M. (2011). Juvenile idiopathic arthritis: Can you recognize this complex diagnosis? Journal of the American Academy of Physician Assistants, 24 (1), 22–27. doi: http://doi.org/10.1097/01720610-201101000-00005

Martini, A. (2012). It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Annals of the Rheumatic Diseases, 71 (9), 1437–1439. doi: http://doi.org/10.1136/annrheumdis-2012-201388

Dueckers, G., Guellac, N., Arbogast, M., Dannecker, G., Foeldvari, I., Frosch, M. et. al. (2011). German evidence and consensus based guidelines 2010 for the treatment of juvenile idiopathic arthritis (JIA). Pediatric Rheumatology, 9, 181. doi: http://doi.org/10.1186/1546-0096-9-s1-p181

Lin, Y.-T., Wang, C.-T., Gershwin, M. E., Chiang, B.-L. (2011). The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmunity Reviews, 10 (8), 482–489. doi: http://doi.org/10.1016/j.autrev.2011.02.001

Omar, A., Abo-Elyoun, I., Hussein, H., Nabih, M., Atwa, H., Gad, S., Emad, Y. (2013). Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): Correlations with disease activity and severity of joint damage (a multicenter trial). Joint Bone Spine, 80 (1), 38–43. doi: http://doi.org/10.1016/j.jbspin.2012.03.008

Rosendahl, K. (2011). Juvenile idiopathic arthritis–recent advances. Pediatric Radiology, 41, 110–112. doi: http://doi.org/10.1007/s00247-011-2054-y

👁 259
⬇ 211
How to Cite
Vyzhga, Y. (2018). EVALUATION OF THE MAIN DATA OF INFLAMMATORY RESPONSE TO THE BASE THERAPY OF THE JUVENILE IDIOPATHIC ARTHRITIS. Technology Transfer: Innovative Solutions in Medicine, 6-8. https://doi.org/10.21303/2585-663.2018.00762
Medicine and Dentistry